Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Free Cash Flow (2020 - 2026)

Opus Genetics has reported Free Cash Flow over the past 12 years, most recently at -$12.7 million for Q1 2026.

  • Quarterly Free Cash Flow fell 41.51% to -$12.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$39.0 million through Mar 2026, down 35.11% year-over-year, with the annual reading at -$35.3 million for FY2025, 37.84% down from the prior year.
  • Free Cash Flow was -$12.7 million for Q1 2026 at Opus Genetics, down from -$9.8 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at $28.8 million in Q4 2022 and troughed at -$12.7 million in Q1 2026.
  • The 5-year median for Free Cash Flow is -$5.7 million (2024), against an average of -$3.6 million.
  • Year-over-year, Free Cash Flow soared 609.94% in 2022 and then plummeted 837.31% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at $28.8 million in 2022, then tumbled by 84.2% to $4.5 million in 2023, then crashed by 263.54% to -$7.4 million in 2024, then crashed by 32.2% to -$9.8 million in 2025, then dropped by 29.43% to -$12.7 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Free Cash Flow are -$12.7 million (Q1 2026), -$9.8 million (Q4 2025), and -$6.2 million (Q3 2025).